Fredag 14 Mars | 16:51:17 Europe / Stockholm

Kalender

Est. tid*
2025-08-28 08:00 Kvartalsrapport 2025-Q2
2025-04-07 N/A X-dag ordinarie utdelning AIFORIA 0.00 EUR
2025-04-04 N/A Årsstämma
2025-03-07 - Bokslutskommuniké 2024
2024-08-29 - Kvartalsrapport 2024-Q2
2024-04-05 - X-dag ordinarie utdelning AIFORIA 0.00 EUR
2024-04-04 - Årsstämma
2024-03-07 - Bokslutskommuniké 2023
2023-08-25 - Kvartalsrapport 2023-Q2
2023-03-31 - X-dag ordinarie utdelning AIFORIA 0.00 EUR
2023-03-30 - Årsstämma
2023-03-02 - Bokslutskommuniké 2022
2022-08-25 - Kvartalsrapport 2022-Q2
2022-04-06 - X-dag ordinarie utdelning AIFORIA 0.00 EUR
2022-04-05 - Årsstämma
2022-03-02 - Bokslutskommuniké 2021

Beskrivning

LandFinland
ListaFirst North Finland
SektorInformationsteknik
IndustriProgramvara
Aiforia Technologies utrustar patologer och forskare i prekliniska och kliniska laboratorier med programvara för att översätta bilder till upptäckter, beslut och diagnoser. Bolagets produkter och tjänster används för medicinsk bildanalys, över en mängd olika områden från onkologi till neurovetenskap. Aiforia Technologies har sitt huvudkontor i Finland.
2025-02-18 10:15:00

Aiforia Technologies Oyj Company Release February 18, 2025 at 11:15am EET

Share subscriptions based on stock options 2016A 

A total of 20,000 Aiforia Technologies Plc’s new shares has been subscribed for with the Stock Options 2016A on January 13, 2025. For subscriptions made with the stock options 2016A the entire subscription price of EUR 400.00 will be entered in the reserve for invested unrestricted equity.

After the trade registration the total amount of shares is 28,934,467.

The shares subscribed for under the stock options 2016A have been registered in the Trade Register on February 18, 2025, as of which date the new shares will establish shareholder rights. 

The shares will be traded in the Nasdaq Helsinki Plc’s First North Growth Market Finland -marketplace as an additional lot with the company’s old shares as of February 19, 2025.

The terms and conditions of stock options are available on the company's website at https://www.aiforia.com/.

Further inquiries

Veli-Matti Parkkonen, CFO, Aiforia Technologies Plc
tel. +358 405 009 878
https://investors.aiforia.com/

 

Certified Adviser

UB Corporate Finance Ltd

ubcf@unitedbankers.fi

 

About Aiforia

Aiforia is a trusted provider of deep learning artificial intelligence (AI) solutions for pathology. Aiforia delivers software solutions that elevate diagnostic capabilities in image analysis, enabling remarkable medical discoveries now and in the future. With thousands of AI models already developed on the Aiforia platform for research use and several diagnostic solutions deployed, Aiforia is already significantly impacting pathology and healthcare.

Founded in 2013, Aiforia is a publicly traded company operating internationally with thousands of platform users across the globe. The company is headquartered in Helsinki, Finland, with offices in Cambridge, Massachusetts, and Rochester, Minnesota, and local representatives across Europe and North America. The diverse team at Aiforia includes experienced pathologists, medical scientists, AI and software developers, and a dedicated commercial team. Together, they are working to transform pathology with AI, enabling better care for each patient.

Find out more at www.aiforia.com